Criteria, prevalence, and phenotypes of polycystic ovary syndrome
Tóm tắt
Từ khóa
Tài liệu tham khảo
Azziz, 2004, The prevalence and features of the polycystic ovary syndrome in an unselected population, J Clin Endocrinol Metab, 89, 2745, 10.1210/jc.2003-032046
Yildiz, 2012, Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria, Hum Reprod, 27, 3067, 10.1093/humrep/des232
Puurunen, 2011, Unfavorable hormonal, metabolic, and inflammatory alterations persist after menopause in women with PCOS, J Clin Endocrinol Metab, 96, 1827, 10.1210/jc.2011-0039
Diamanti-Kandarakis, 2012, Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications, Endocr Rev, 33, 981, 10.1210/er.2011-1034
Ferriman, 1983, The aetiology of oligomenorrhoea and/or hirsuties: a study of 467 patients, Postgrad Med J, 59, 17, 10.1136/pgmj.59.687.17
Balen, 1995, Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients, Hum Reprod, 10, 2107, 10.1093/oxfordjournals.humrep.a136243
DeUgarte, 2005, Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment, Fertil Steril, 83, 1454, 10.1016/j.fertnstert.2004.11.070
Norman, 2001, Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome, Hum Reprod, 16, 1995, 10.1093/humrep/16.9.1995
Krentz, 2007, Searching for polycystic ovary syndrome in postmenopausal women: evidence of a dose-effect association with prevalent cardiovascular disease, Menopause, 14, 284, 10.1097/GME.0b013e31802cc7ab
Legro, 2001, Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome, Am J Med, 111, 607, 10.1016/S0002-9343(01)00948-2
Wild, 2000, Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study, Clin Endocrinol (Oxf), 52, 595, 10.1046/j.1365-2265.2000.01000.x
Jedel, 2010, Anxiety and depression symptoms in women with polycystic ovary syndrome compared with controls matched for body mass index, Hum Reprod, 25, 450, 10.1093/humrep/dep384
Boomsma, 2006, A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome, Hum Reprod Update, 12, 673, 10.1093/humupd/dml036
Qin, 2013, Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysis, Reprod Biol Endocrinol, 11, 56, 10.1186/1477-7827-11-56
Kjerulff, 2011, Pregnancy outcomes in women with polycystic ovary syndrome: a metaanalysis, Am J Obstet Gynecol, 204, 558.e1, 10.1016/j.ajog.2011.03.021
Hart, 2015, The potential implications of a PCOS diagnosis on a woman’s long-term health using data linkage, J Clin Endocrinol Metab, 100, 911, 10.1210/jc.2014-3886
Zawadzki, 1992, Diagnostic criteria for polycystic ovary syndrome; towards a rational approach
2004, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome, Fertil Steril, 81, 19, 10.1016/j.fertnstert.2003.10.004
2004, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS), Hum Reprod, 19, 41, 10.1093/humrep/deh098
Azziz, 2006, Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature, J Clin Endocrinol Metab, 91, 781, 10.1210/jc.2005-2153
Franks, 2006, Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria, J Clin Endocrinol Metab, 91, 786, 10.1210/jc.2005-2501
National Institutes of Health. Evidence-based methodology workshop on polycystic ovary syndrome, December 3-5, 2012. Executive summary. Available at: https://prevention.nih.gov/docs/programs/pcos/FinalReport.pdf. Accessed March 1, 2016.
Azziz, 2006, Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline, J Clin Endocrinol Metab, 91, 4237, 10.1210/jc.2006-0178
Azziz, 2009, The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report, Fertil Steril, 91, 456, 10.1016/j.fertnstert.2008.06.035
Broekmans, 2006, PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors, BJOG, 113, 1210, 10.1111/j.1471-0528.2006.01008.x
Rosencrantz, 2011, Clinical evidence for predominance of delta-5 steroid production in women with polycystic ovary syndrome, J Clin Endocrinol Metab, 96, 1106, 10.1210/jc.2010-2200
Georgopoulos, 2014, Elevated serum androstenedione is associated with a more severe phenotype in women with polycystic ovary syndrome (PCOS), Hormones (Athens), 13, 213, 10.1007/BF03401335
Carmina, 2005, Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters, J Clin Endocrinol Metab, 90, 2545, 10.1210/jc.2004-2279
Legro, 2013, Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab, 98, 4565, 10.1210/jc.2013-2350
Bridges, 1993, Standards for ovarian volume in childhood and puberty, Fertil Steril, 60, 456, 10.1016/S0015-0282(16)56160-3
Fruzzetti, 2015, Ovarian volume in normal and hyperandrogenic adolescent women, Fertil Steril, 104, 196, 10.1016/j.fertnstert.2015.03.026
Rosenfield, 2000, Diagnosis of the polycystic ovary syndrome in adolescence: comparison of adolescent and adult hyperandrogenism, J Pediatr Endocrinol Metab, 13, 1285
Glueck, 2015, Adolescent oligomenorrhea (age 14-19) tracks into the third decade of life (age 20-28) and predicts increased cardiovascular risk factors and metabolic syndrome, Metabolism, 64, 539, 10.1016/j.metabol.2015.01.005
Rosenfield, 2015, The diagnosis of polycystic ovary syndrome in adolescents, Pediatrics, 136, 1154, 10.1542/peds.2015-1430
Salameh, 2010, Validation of a total testosterone assay using high-turbulence liquid chromatography tandem mass spectrometry: total and free testosterone reference ranges, Steroids, 75, 169, 10.1016/j.steroids.2009.11.004
DeUgarte, 2006, Degree of facial and body terminal hair growth in unselected black and white women: toward a populational definition of hirsutism, J Clin Endocrinol Metab, 91, 1345, 10.1210/jc.2004-2301
Fauser, 2012, Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group, Fertil Steril, 97, 28, 10.1016/j.fertnstert.2011.09.024
Elting, 2000, Women with polycystic ovary syndrome gain regular menstrual cycles when ageing, Hum Reprod, 15, 24, 10.1093/humrep/15.1.24
Elting, 2003, Aging women with polycystic ovary syndrome who achieve regular menstrual cycles have a smaller follicle cohort than those who continue to have irregular cycles, Fertil Steril, 79, 1154, 10.1016/S0015-0282(03)00152-3
Alsamarai, 2009, Criteria for polycystic ovarian morphology in polycystic ovary syndrome as a function of age, J Clin Endocrinol Metab, 94, 4961, 10.1210/jc.2009-0839
Pinola, 2015, Androgen profile through life in women with polycystic ovary syndrome: a Nordic multicenter collaboration study, J Clin Endocrinol Metab, 100, 3400, 10.1210/jc.2015-2123
Rosner, 2007, Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement, J Clin Endocrinol Metab, 92, 405, 10.1210/jc.2006-1864
Knochenhauer, 1998, Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study, J Clin Endocrinol Metab, 83, 3078
March, 2010, The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria, Hum Reprod, 25, 544, 10.1093/humrep/dep399
Boyle, 2012, Prevalence of polycystic ovary syndrome in a sample of Indigenous women in Darwin, Australia, Med J Aust, 196, 62, 10.5694/mja11.10553
Gabrielli, 2012, Polycystic ovary syndrome in Salvador, Brazil: a prevalence study in primary healthcare, Reprod Biol Endocrinol, 10, 96, 10.1186/1477-7827-10-96
Chen, 2008, Prevalence of polycystic ovary syndrome in unselected women from southern China, Eur J Obstet Gynecol Reprod Biol, 139, 59, 10.1016/j.ejogrb.2007.12.018
Ma, 2010, Characteristics of abnormal menstrual cycle and polycystic ovary syndrome in community and hospital populations, Chin Med J (Engl), 123, 2185
Li, 2013, Prevalence of polycystic ovary syndrome in women in China: a large community-based study, Hum Reprod, 28, 2562, 10.1093/humrep/det262
Zhang, 2009, Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale Chinese population, BJOG, 116, 1633, 10.1111/j.1471-0528.2009.02347.x
Lauritsen, 2014, The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone, Hum Reprod, 29, 791, 10.1093/humrep/det469
Zhuang, 2014, Prevalence of the polycystic ovary syndrome in female residents of Chengdu, China, Gynecol Obstet Invest, 77, 217, 10.1159/000358485
Tehrani, 2014, The prevalence of metabolic disorders in various phenotypes of polycystic ovary syndrome: a community based study in Southwest of Iran, Reprod Biol Endocrinol, 12, 89, 10.1186/1477-7827-12-89
Mehrabian, 2011, The prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria, Endokrynol Pol, 62, 238
Rashidi, 2014, To what extent does the use of the Rotterdam criteria affect the prevalence of polycystic ovary syndrome? A community-based study from the Southwest of Iran, Eur J Obstet Gynecol Reprod Biol, 174, 100, 10.1016/j.ejogrb.2013.12.018
Sanchon, 2012, Prevalence of functional disorders of androgen excess in unselected premenopausal women: a study in blood donors, Hum Reprod, 27, 1209, 10.1093/humrep/des028
Moran, 2010, Prevalence of polycystic ovary syndrome and related disorders in Mexican women, Gynecol Obstet Invest, 69, 274, 10.1159/000277640
Musmar, 2013, Epidemiology of polycystic ovary syndrome: a cross sectional study of university students at An-Najah national university-Palestine, Reprod Biol Endocrinol, 11, 47, 10.1186/1477-7827-11-47
Asuncion, 2000, A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain, J Clin Endocrinol Metab, 85, 2434
Kumarapeli, 2008, A simple screening approach for assessing community prevalence and phenotype of polycystic ovary syndrome in a semi-urban population in Sri Lanka, Am J Epidemiol, 168, 321, 10.1093/aje/kwn137
Michelmore, 1999, Polycystic ovaries and associated clinical and biochemical features in young women, Clin Endocrinol (Oxf), 51, 779, 10.1046/j.1365-2265.1999.00886.x
Goodarzi, 2005, Polycystic ovary syndrome in Mexican-Americans: prevalence and association with the severity of insulin resistance, Fertil Steril, 84, 766, 10.1016/j.fertnstert.2005.03.051
Sirmans, 2014, Epidemiology and comorbidities of polycystic ovary syndrome in an indigent population, J Investig Med, 62, 868, 10.1097/01.JIM.0000446834.90599.5d
Tehrani, 2011, The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study, Reprod Biol Endocrinol, 9, 39, 10.1186/1477-7827-9-39
Dewailly, 2014, Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society, Hum Reprod Update, 20, 334, 10.1093/humupd/dmt061
Azziz, 2011, Polycystic ovary syndrome: an ancient disorder?, Fertil Steril, 95, 1544, 10.1016/j.fertnstert.2010.09.032
Baldani, 2013, Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in the Croatian population, Coll Antropol, 37, 477
Belosi, 2006, Is the PCOS diagnosis solved by ESHRE/ASRM 2003 consensus or could it include ultrasound examination of the ovarian stroma?, Hum Reprod, 21, 3108, 10.1093/humrep/del306
Cupisti, 2011, The different phenotypes of polycystic ovary syndrome: no advantages for identifying women with aggravated insulin resistance or impaired lipids, Exp Clin Endocrinol Diabetes, 119, 502, 10.1055/s-0031-1277136
Dewailly, 2006, Oligoanovulation with polycystic ovaries but not overt hyperandrogenism, J Clin Endocrinol Metab, 91, 3922, 10.1210/jc.2006-1054
Mehrabian, 2011, The prevalence of metabolic syndrome and insulin resistance according to the phenotypic subgroups of polycystic ovary syndrome in a representative sample of Iranian females, J Res Med Sci, 16, 763
Hsu, 2007, Diagnostic criteria for polycystic ovary syndrome in Taiwanese Chinese women: comparison between Rotterdam 2003 and NIH 1990, Fertil Steril, 88, 727, 10.1016/j.fertnstert.2006.11.149
Shroff, 2007, Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria, Fertil Steril, 88, 1389, 10.1016/j.fertnstert.2007.01.032
Melo, 2011, The frequency of metabolic syndrome is higher among PCOS Brazilian women with menstrual irregularity plus hyperandrogenism, Reprod Sci, 18, 1230, 10.1177/1933719111414205
Ehrmann, 2006, Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome, J Clin Endocrinol Metab, 91, 48, 10.1210/jc.2005-1329
Brower, 2013, The severity of menstrual dysfunction as a predictor of insulin resistance in PCOS, J Clin Endocrinol Metab, 98, E1967, 10.1210/jc.2013-2815
Legro, 2005, Polycystic ovaries are common in women with hyperandrogenic chronic anovulation but do not predict metabolic or reproductive phenotype, J Clin Endocrinol Metab, 90, 2571, 10.1210/jc.2004-0219
Kim, 2014, Complete phenotypic and metabolic profiles of a large consecutive cohort of untreated Korean women with polycystic ovary syndrome, Fertil Steril, 101, 1424, 10.1016/j.fertnstert.2014.01.049
Welt, 2006, Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features, J Clin Endocrinol Metab, 91, 4842, 10.1210/jc.2006-1327
Diamanti-Kandarakis, 2007, Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): a prospective study of 634 women with PCOS, Clin Endocrinol (Oxf), 67, 735, 10.1111/j.1365-2265.2007.02954.x
Moran, 2009, Metabolic features of the reproductive phenotypes of polycystic ovary syndrome, Hum Reprod Update, 15, 477, 10.1093/humupd/dmp008
Goverde, 2009, Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria, Hum Reprod, 24, 710, 10.1093/humrep/den433
Jones, 2012, Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance, J Clin Endocrinol Metab, 97, 3709, 10.1210/jc.2012-1382
Sahmay, 2013, Serum anti-Mullerian hormone levels in the main phenotypes of polycystic ovary syndrome, Eur J Obstet Gynecol Reprod Biol, 170, 157, 10.1016/j.ejogrb.2013.05.019
Romualdi, 2016, The role of anti-mullerian hormone in the characterization of the different polycystic ovary syndrome phenotypes, Reprod Sci, 23, 655, 10.1177/1933719115611751
Jamil, 2016, Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteria, Arch Gynecol Obstet, 293, 447, 10.1007/s00404-015-3889-5
Panidis, 2015, Associations of menstrual cycle irregularities with age, obesity and phenotype in patients with polycystic ovary syndrome, Hormones (Athens), 14, 431
Rizzo, 2009, Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype, Hum Reprod, 24, 2286, 10.1093/humrep/dep121
Guastella, 2010, Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes, Fertil Steril, 94, 2197, 10.1016/j.fertnstert.2010.02.014
Di Fede, 2009, Influence of sociocultural factors on the ovulatory status of polycystic ovary syndrome, Fertil Steril, 91, 1853, 10.1016/j.fertnstert.2008.02.161
Chae, 2008, Clinical and biochemical characteristics of polycystic ovary syndrome in Korean women, Hum Reprod, 23, 1924, 10.1093/humrep/den239
Yilmaz, 2011, Anthropometric, clinical and laboratory comparison of four phenotypes of polycystic ovary syndrome based on Rotterdam criteria, J Obstet Gynaecol Res, 37, 1020, 10.1111/j.1447-0756.2010.01478.x
Panidis, 2012, Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study, Hum Reprod, 27, 541, 10.1093/humrep/der418
Wijeyaratne, 2011, Phenotype and metabolic profile of South Asian women with polycystic ovary syndrome (PCOS): results of a large database from a specialist Endocrine Clinic, Hum Reprod, 26, 202, 10.1093/humrep/deq310
Ates, 2013, Different phenotypes of polycystic ovary syndrome in Turkish women: clinical and endocrine characteristics, Gynecol Endocrinol, 29, 931, 10.3109/09513590.2013.819082
Guo, 2010, Cardiovascular and metabolic characteristics of infertile Chinese women with PCOS diagnosed according to the Rotterdam consensus criteria, Reprod Biomed Online, 21, 572, 10.1016/j.rbmo.2010.04.032
Wild, 2010, Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society, J Clin Endocrinol Metab, 95, 2038, 10.1210/jc.2009-2724
Ezeh, 2013, Referral bias in defining the phenotype and prevalence of obesity in polycystic ovary syndrome, J Clin Endocrinol Metab, 98, E1088, 10.1210/jc.2013-1295
Luque-Ramirez, 2015, Referral bias in female functional hyperandrogenism and polycystic ovary syndrome, Eur J Endocrinol, 173, 603, 10.1530/EJE-15-0646